InvestorsHub Logo
Followers 13
Posts 1050
Boards Moderated 0
Alias Born 07/19/2013

Re: None

Thursday, 03/21/2019 3:03:45 PM

Thursday, March 21, 2019 3:03:45 PM

Post# of 163
BioVie, Inc. (BIVI)
Pioneering therapies for advanced liver disease
Non-confidential investor presentation | December 2018

***A new treatment option is emerging for refractory ascites
Based on investigative studies in Italy and Australia
***Terlipressin (BIV201’s active agent) is approved in 40+ countries for
treating related liver cirrhosis complications (HRS & BEV*)

***BIV201 is a new drug candidate in the US
Terlipressin is not available in the US or Japan

***Currently in US phase 2 clinical
trials; seeking to replicate
European & Australian
investigative study results

***BIV201 offers advantages in 40+ countries where
Terlipressin is already approved
Targeting improved efficacy and safety compared to IV bolus dosing

***Clinically de-risked development program
The same therapy that is currently in use in Italy and Australia

***US patent protection
through 2036

***Filed for patents in Japan,
China & Europe

***US Orphan Drug designations for
both ascites and HRS to enable 7
years of market exclusivity

***FDA Fast Track status; will seek
Breakthrough Therapy designation


https://www.biovieinc.com/wp-content/uploads/2019/01/BioVie-Non-Conf-Deck_Dec_2018.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MDGL News